Topics:

Kidney Cancer

Expression of BAP1 could help identify which clear-cell renal cell carcinoma patients diagnosed with low-risk disease are the most likely to progress.

Kidney Cancer

A study of patient preference revealed that patients who participated in a crossover trial of pazopanib and sunitinib for metastatic renal cell carcinoma preferred treatment with pazopanib.

The FGF inhibitor dovitinib failed to improve progression-free survival outcomes as a third-line treatment for patients with metastatic renal cell carcinoma compared with sorafenib, according to the results of a new study.

New research shows that tumors found in obese patients may be more indolent than those in nonobese patients, and this may, in part, be related to alterations in fatty acid metabolism explaining the obesity paradox in clear-cell renal cell carcinoma.

The order of the sequencing of sorafenib and sunitinib for first-line and second-line therapy did not affect progression-free and overall survival for patients with advanced renal cell carcinoma.

Expressive writing is a brief and simple intervention that a recent study showed helped to reduce cancer-related symptoms and improved physical functioning in patients with renal cell carcinoma.

Expression of BAP1 could help identify which clear-cell renal cell carcinoma patients diagnosed with low-risk disease are the most likely to progress.

Pages

Subscribe to
Please Wait 20 seconds or click here to close